Type 2 Diabetes

At HiD 2022, Dr. Budoff discusses the use and utility of coronary calcium scoring for risk stratification

Dr. Martin explores the explosion of new consumer technologies and how to close the gap in disparities between data collection and using the data in practice.

Dr. Ray discusses the impact of current practice on cholesterol goal attainment and what more needs to be done.

Dr. Green discusses the potential of combination therapy to reduce cardiovascular and kidney outcomes in people with type 2 diabetes.

Dr. Joseph discusses modalities to address cardiometabolic disease in individuals around the country, from lifestyle management to policy-level changes.

In this episode, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss their experiences with prescribing tirzepatide (Mounjaro) and what issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.

Dr. Gregory Weiss provides perspective on recent data detailing the acceleration of heart failure progression associated with a diagnosis of diabetes mellitus.

There were also significant social determinants including race and religion discordance between the healthcare provider and patient and caregiver responsibilities toward others.

An analysis of data from Medicare Fee-for-Service beneficiaries suggests patients attending annual wellness visits were 36% less likely to require lower limb amputation than their counterparts who did not attend an annual wellness visit that year.

An analysis of the National Inpatient Sample details the statistically significant increases in the risk of experiencing myocardial infarction, PCI, or CABG in patients with prediabetes compared to their normoglycemic counterparts.

Erika Petersen, MD, discusses 24-month data from SENZA-PDN and provides perspective on the potential for spinal cord stimulation for reducing pain from diabetic peripheral neuropathy in real-world settings.

An analysis of 20 randomized clinical trials comparing empagliflozin against placebo therapy in patients with type 2 diabetes suggests use of the SGLT2 inhibitor could reduce risk of developing kidney stones by nearly 40%.

An analysis of the SEARCH for Youth in Diabetes presented at ENDO 2022 details historic and contemporary disparities in insulin pump use for pediatric type 1 diabetes based on racial/ethnic background, household income, and insurance type.

On June 12, the Endocrine Society released new guidance for management of hyperglycemia in adult patients in noncritical care settings, which are cosponsored by the AACE, ADA, ADCES, and ESE.

An analysis of the National Inpatient Sample at ENDO 2022 provides insight into the risk of myocardial infarction associated with prediabetes compared against normoglycemic patients.

In the fourth and final episode from ADA 2022, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.

In the third special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, Jasmine Gonzalvo, PharmD, joins hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss prevailing barriers in diabetes management, including access to new pharmacologic agents as well as newer diabetes technologies.

In our second special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, hosts Drs. Diana Isaacs and Natalie Bellini are joined by Gary Scheiner, MS, CDE. Clinical director of Integrated Diabetes Services, author of multiple books, including Think Like a Pancreas: A Practical Guide to Managing Diabetes with Insulin, and former Diabetes Educator of the Year, Scheiner joins Diabetes Dialogue to provide a deep dive into the largest diabetes meeting of the year from the view of a diabetes care and education specialist.

Patients with diabetic retinopathy showed significantly higher updated first-year HbA1c and at follow-up compared to those free from DR.

Panelists consider the importance of long-term approaches to monitoring hypoglycemic episodes and discuss the role of education and awareness, patient questionnaires, and effective communication with physicians.

A higher percentage of participants in the pooled dulaglutide group had a glycated hemoglobin level of <7.0% than the placebo group at week 26 of the AWARD-PEDS trial.

Key thought leaders in endocrinology review different signs and symptoms of hypoglycemia across vulnerable patient populations and discuss factors that may impact the pharmacologic management of blood glucose levels.

The late-breaking data show SGLT2is are underutilized in patients with heart failure with or without type 2 diabetes despite guideline recommendations.

Eli Lilly and Company announced tirzepatide (Mounjaro) is now available in US pharmacies. We sat down with SURPASS-2 principal investigator Juan Frias, MD, at ADA 2022 and got his perspective on the potential of tirzepatide and what hesitancies clinicians may have related to the prescription of the dual GIP/GLP-1 receptor agonist.